Bortezomib, Dexamethasone, and High-Dose Melphalan as Conditioning for Stem Cell Transplantation in Young Japanese Multiple Myeloma Patients: A Pilot Study

Takezako, Naoki; Sekiguchi, Naohiro; Nagata, Akihisa; Homma, Chiho; Noto, Satoshi; Miwa, Akiyoshi

doi:10.1007/s12288-012-0177-4

Cited by 3 publications

(2 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…29 Recently, there are several studies that investigated bortezomib and melphalan combination as the conditioning regimen. 12–21…”

Section: Discussionmentioning

confidence: 99%

“…10,11 Bortezomib and HDM combination as conditioning regimen has been investigated by many other investigators. 12–21 The previous studies showed comparable engraftment kinetics and toxicity profiles in Bor-HDM conditioning regimen when compared to HDM. 12–14,20 The aim of this retrospective study was to evaluate the hematologic recovery and toxicity profile in HDM and Bor-HDM conditioning regimen in the MM patients undergoing AHSCT.…”

Section: Introductionmentioning

confidence: 91%

See 1 more Smart Citation

Comparison of conditioning regimen toxicities among autologous stem cell transplantation eligible multiple myeloma patients: High-dose melphalan versus high-dose melphalan and bortezomib

Aypar

İzzettin

Akı

et al. 2017

J Oncol Pharm Pract

View full text Add to dashboard Cite

Background Autologous hematopoietic stem cell transplantation (AHSCT) remains the standard of care for younger patients with multiple myeloma (MM). Currently, high-dose melphalan (HDM) is recommended as conditioning regimen before AHSCT. Preclinical data suggest that combining bortezomib and melphalan has synergistic effect against multiple myeloma cells. Bortezomib and HDM (Bor-HDM) combination as conditioning regimen has been investigated by many other investigators. Objective In this retrospective study, we aimed to compare transplant-related toxicities and hematologic recovery of HDM and Bor-HDM conditioning regimens. Method We retrospectively evaluated hematologic recovery and toxicity profile in patients with MM who received AHSCT with either HDM ( n = 114) or Bor-HDM ( n = 53) conditioning regimen. Results Nonhematologic toxicities were comparable between HDM and Bor-HDM conditioning regimen, except mucositis and diarrhea being more frequent in the Bor-HDM group. Neutrophil and platelet engraftment time and duration of hospital stay were significantly shorter for HDM regimen. Conclusions In this retrospective analysis, we observed engraftment kinetics and duration of hospitalization were significantly worse in Bor-HDM conditioning regimen with manageable toxicities. Randomized studies are needed to further compare Bor- HDM regimen to HDM in terms of response rates, toxicities, and transplant-related mortality.

show abstract

“…29 Recently, there are several studies that investigated bortezomib and melphalan combination as the conditioning regimen. 12–21…”

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 91%

Comparison of conditioning regimen toxicities among autologous stem cell transplantation eligible multiple myeloma patients: High-dose melphalan versus high-dose melphalan and bortezomib

Aypar

İzzettin

Akı

et al. 2017

J Oncol Pharm Pract

View full text Add to dashboard Cite

show abstract

RETRACTED ARTICLE: Cdc25C/cdc2/cyclin B, raf/MEK/ERK and PERK/eIF2α/CHOP pathways are involved in forskolin-induced growth inhibition of MM.1S cells by G2/M arrest and mitochondrion-dependent apoptosis

Yang¹,

Jiang²,

Li³

et al. 2021

Cell Cycle

View full text Add to dashboard Cite

Autologous stem cell transplantation for multiple myeloma

Nakamura

Sunami

2014

Journal of Hematopoietic Cell Transplantation

View full text Add to dashboard Cite

Autologous stem cell transplantation (ASCT) is known to be superior to conventional chemotherapies and has been established as a standard of care for young patients with multiple myeloma. In the 2000s, novel agents such as thalidomide, bortezomib, and lenalidomide became clinically available, and several clinical trials using these drugs as induction therapy, conditioning regimen, and post-transplant consolidation and maintenance therapy have been reported, leading to an increasing improvement in the treatment results compared to the conventional therapies. Future changes in the therapeutic strategies using the novel agents will increase the CR rate and prolong PFS and OS. The 2 nd generation drugs including carfilzomib and pomalidomide, as well as antibody drugs such as elotuzumab and daratumumab, are now under development. These drugs are expected to further improve the treatment results.

show abstract

Bortezomib, Dexamethasone, and High-Dose Melphalan as Conditioning for Stem Cell Transplantation in Young Japanese Multiple Myeloma Patients: A Pilot Study

Cited by 3 publications

References 28 publications

Comparison of conditioning regimen toxicities among autologous stem cell transplantation eligible multiple myeloma patients: High-dose melphalan versus high-dose melphalan and bortezomib

Comparison of conditioning regimen toxicities among autologous stem cell transplantation eligible multiple myeloma patients: High-dose melphalan versus high-dose melphalan and bortezomib

RETRACTED ARTICLE: Cdc25C/cdc2/cyclin B, raf/MEK/ERK and PERK/eIF2α/CHOP pathways are involved in forskolin-induced growth inhibition of MM.1S cells by G2/M arrest and mitochondrion-dependent apoptosis

Autologous stem cell transplantation for multiple myeloma

Contact Info

Product

Resources

About